Analystreport

ProQR Therapeutics NV (NASDAQ: PRQR) was given a new $40.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock.

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com